In a recent study, the BRCA1-∆11q splice variant, missing most exon 11, which contains an inactivating mutation of the BRCA1 gene, has been attributed to acquired resistance to PARPi, partly diminishing the sensitivity to PARPi and cisplatin in breast cancer. The gene discussed is BRCA1; the disease is breast cancer.